CIK 0001453687
- Non-accelerated filer
- Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-13 | Singer Michael Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +11,316.26 | 11,316.26 | ||
| 2023-11-13 | Singer Michael Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +1,672.39 | 1,672.39 | ||
| 2023-11-13 | Singer Michael Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +210.15 | 210.15 | ||
| 2023-11-13 | Singer Michael Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +2,837.05 | 2,837.05 | ||
| 2023-11-13 | Singer Michael Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +2,837.05 | 2,837.05 | ||
| 2023-11-13 | Singer Michael Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +436.07 | 436.07 | ||
| 2023-11-13 | Kalayoglu Murat Director | Grant or award | +257,739 | 257,739 | ||
| 2023-11-13 | Kalayoglu Murat Director | Other acquisition | +3,303,699 | 3,303,699 | ||
| 2023-11-13 | Kalayoglu Murat Director | Grant or award · Series A Non-Voting Convertible Preferred Stock | +14,755.61 | 14,755.61 | ||
| 2023-11-13 | Kalayoglu Murat Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +189,136.77 | 189,136.77 | ||
| 2023-11-13 | Kalayoglu Murat Director | Purchase · Series A Non-Voting Convertible Preferred Stock | +619.63 | $249,999.98 | $154.9M | 619.63 |
| 2023-11-13 | Miljkovic Milos Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +2,565.87 | 2,565.87 | ||
| 2023-09-25 | Brunn Carsten President and CEO | Sale | −2,932 | $1.06 | $3K | 783,081 |
| 2023-09-25 | TRABER PETER G Chief Medical Officer | Sale | −705 | $1.06 | $747 | 451,826 |
| 2023-05-31 | Kishimoto Takashi Kei Chief Scientific Officer | Gift | −26,500 | 251,816 | ||
| 2023-05-31 | Kishimoto Takashi Kei Chief Scientific Officer | Gift | −26,500 | 225,316 | ||
| 2023-05-30 | Kishimoto Takashi Kei Chief Scientific Officer | Gift | −43,000 | 321,316 | ||
| 2023-05-30 | Kishimoto Takashi Kei Chief Scientific Officer | Gift | −43,000 | 278,316 | ||
| 2023-01-05 | Brunn Carsten President and CEO | Sale | −13,396 | $1.13 | $15K | 786,090 |
| 2023-01-05 | Brunn Carsten President and CEO | Sale | −77 | $1.12 | $86 | 786,013 |
Page 18 of 25 · 495 trades